治療・社会復帰支援研究部門 業績集

トップページ > 病態解析研究 > 業績集

治療・社会復帰支援研究部門メニュー

原著 2017年

  1. Shiina, A., Tomoto, A., Omiya, S., Sato, A., Iyo, M., Igarashi, Y. (2017) Differences between British and Japanese perspectives on forensic mental health systems: A preliminary study World Journal of Psychiatry. World Journal of Psychiatry. 22; 7(1): 8–11.

原著 2016年

  1. Hashimoto, K., Yoshida, T., Ishikawa, M., Fujita, Y., Niitsu, T., Nakazato, M., Watanabe, H., Sasaki, T., Shiina, A., Hashimoto, T., Kanahara, N., Hasegawa, T., Enohara, M., Kimura, A., Iyo, M. (2016 Jun) Increased serum levels of serine enantiomers in patients with depression. Acta Neuropsychiatrica.28(3):173-8.
  2. Sutoh C, Koga Y, Kimura H, Kanahara N, Numata N, Hirano Y, Matsuzawa D, Iyo M, Nakazato M, Shimizu E.(2016 Jan) Repetitive Transcranial Magnetic Stimulation Changes Cerebral Oxygenation on the Left Dorsolateral Prefrontal Cortex in Bulimia Nervosa: A Near-Infrared Spectroscopy Pilot Study. European Eating Disorders Review.24(1):83-8.
  3. Saito T, Ikeda M, Mushiroda T, Ozeki T, Kondo K, Shimasaki A, Kawase K, Hashimoto S, Yamamori H, Yasuda Y, Fujimoto M, Ohi K, Takeda M, Kamatani Y, Numata S, Ohmori T, Ueno S, Makinodan M, Nishihata Y, Kubota M,Kimura T, Kanahara N, Hashimoto N, Fujita K, Nemoto K, Fukao T, Suwa T, Noda T, Yada Y, Takaki M, Kida N, Otsuru T, Murakami M, Takahashi A, Kubo M, Hashimoto R, Iwata N.(2016 Feb 11) Pharmacogenomic Study of Clozapine-Induced Agranulocytosis/Granulocytopenia in a Japanese Population. Biological Psychiatry.pii: S0006-3223(15)01041-0.
  4. Yamanaka H, Kanahara N, Suzuki T, Takase M, Moriyama T, Watanabe H, Hirata T, Asano M, Iyo M.(2016 Feb) Impact of dopamine supersensitivity psychosis in treatment-resistant schizophrenia: An analysis of multi-factors predicting long-term prognosis. Schizophrenia Research.170(2-3):252-8.
  5. Nakata, Y., Kanahara. N., Kimura, H., Watanabe, H., Iyo, M. (2016) Efficacy of clozapine on dopamine supersensitivity psychosis in schizophrenia. Int. Clin. Psychopharmacol. 32(3): 169–173.
  6. Tachibana, M., Niitsu, T., Watanabe, M., Hashimoto, T., Kanahara. N., Ishikawa, M., Iyo, M. (2016) Effectiveness of blonanserin for patients with drug treatment-resistant schizophrenia and dopamine supersensitivity: A retrospective analysis. Asian J. Psychiatry. 24: 28-32.
  7. Matsumoto, J., Hirano, Y., Hashimoto, K., Ishima, T., Kanahara. N., Niitsu, T., Shiina, A., Hashimoto, T., Sato, Y., Yokote, K., Murano, S., Kimura, H., Hosoda, Y., Shimizu, E., Iyo, M., Nakazato, M. (2016) Altered serum level of matrix metalloproteinase-9 and its association with decision-making in eating disorders. Psychiatry Clin. Neurosci. 71(2): 124-134.
  8. Sasaki, T., Hashimoto, K., Oda, Y., Ishima, T., Yakita, M., Kurata, T., Kunou, M., Takahashi, J., Kamata, Y., Kimura, A., Niitsu, T., Komatsu, H., Hasegawa, T., Shiina, A., Hashimoto, T., Kanahara. N., Shimizu, E., Iyo, M. (2016) Increased Serum Levels of Oxytocin in 'Treatment Resistant Depression in Adolescents (TRDIA)’ Group. PLoS One. 11 (8): e0160767.
  9. Kimura, H., Kanahara. N., Sasaki, T., Komatsu, N., Ishige, M., Muneoka, K., Ino, H., Yoshimura, K., Yamanaka, H., Suzuki, T., Komatsu, H., Watanabe, H., Shimizu, E., Iyo, M. (2016) Risperidone long-acting injectable in the treatment of treatment-resistant schizophrenia with dopamine supersensitivity psychosis: Results of a 2-year prospective study, including an additional 1-year follow-up. J. Psychopharmacol. 30 (8): 795-802.
  10. Kimura, H., Kanahara. N., Takase, M., Yoshida, T., Watanabe, H., Iyo, M. (2016) A randomized, sham-controlled study of high frequency rTMS for auditory hallucination in schizophrenia. Psychiatry Res. 241: 190-194.
  11. Kanahara, N., Kimura, H., Iyo, M. (2016) Reply to "concern over your recent paper on risperidone long-acting injectable for treatment-resistant schizophrenia". Schizophr. Res. 173 (1-2): 118.

原著 2015年

  1. Hashimoto T, Sakurai D, Oda Y, Hasegawa T, Kanahara N, Sasaki T, Komatsu H, Takahashi J, Oiwa T, Sekine Y, Watanabe H, Iyo M.(2015 Dec) Milnacipran treatment and potential biomarkers in depressed patients following an initial SSRI treatment failure: a prospective, open-label, 24-week study. Neuropsychiatric Disease and Treatment.10;11:3031-40.
  2. Oda Y, Tadokoro S, Takase M, Kanahara N, Watanabe H, Shirayama Y, Hashimoto K, Iyo M.(2015 Dec) G protein-coupled receptor kinase 6/β-arrestin 2 system in a rat model of dopamine supersensitivity psychosis. Journal of Psychopharmacology.29(12):1308-13.
  3. Yamada K, Hattori E, Iwayama Y, Toyota T, Iwata Y, Suzuki K, Kikuchi M, Hashimoto T, Kanahara N, Mori N, Yoshikawa T.(2015 Oct) Population-dependent contribution of the major histocompatibility complex region to schizophrenia susceptibility. Schizophrenia Research.168(1-2):444-9.
  4. Sasaki T, Hashimoto K, Oda Y, Ishima T, Kurata T, Takahashi J, Kamata Y, Kimura H, Niitsu T, Komatsu H, Ishikawa M, Hasegawa T, Shiina A, Hashimoto T, Kanahara N, Shiraishi T, Iyo M.(2015 Aug) Decreased levels of serum oxytocin in pediatric patients with Attention Deficit/Hyperactivity Disorder. Psychiatry Research.30;228(3):746-51.
  5. Oda Y, Kanahara N, Kimura H, Watanabe H, Hashimoto K, Iyo M.(2015 Jul) Genetic association between G protein-coupled receptor kinase 6/β-arrestin 2 and dopamine supersensitivity psychosis in schizophrenia. Neuropsychiatric Disease and Treatment.29;11:1845-51.
  6. Bangel FN, Yamada K, Arai M, Iwayama Y, Balan S, Toyota T, Iwata Y, Suzuki K, Kikuchi M, Hashimoto T, Kanahara N, Mori N, Itokawa M, Stork O, Yoshikawa T.(2015 Jun) Genetic analysis of the glyoxalase system in schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry.3;59:105-10.
  7. Jitoku D, Yamamoto N, Iwayama Y, Toyota T, Miyagi M, Enokida T, Tasaka Y, Umino M, Umino A, Uezato A, Iwata Y, Suzuki K, Kikuchi M, Hashimoto T, Kanahara N, Kurumaji A, Yoshikawa T, Nishikawa T.(2015 Jun) Association study of H2AFZ with schizophrenia in a Japanese case-control sample. Journal of Neural Transmission(Vienna).122(6):915-23.
  8. Suzuki T, Kanahara N, Yamanaka H, Takase M, Kimura H, Watanabe H, Iyo M.(2015 Jun) Dopamine supersensitivity psychosis as a pivotal factor in treatment-resistant schizophrenia. Psychiatry Research.30;227(2-3):278-82.
  9. Takase M, Kanahara N, Oda Y, Kimura H, Watanabe H, Iyo M.(2015 Apr) Dopamine supersensitivity psychosis and dopamine partial agonist: a retrospective survey of failure of switching to aripiprazole in schizophrenia. Journal of Psychopharmacology.29(4):383-9.
  10. Shiina, A., Kanahara, N., Sasaki, T., Oda, Y., Hashimoto, T., Hasegawa, T., Yoshida, T., Iyo, M., Hashimoto, K.(2015 Apr) An Open Study of Sulforaphane-rich Broccoli Sprout Extract in Patients with Schizophrenia. Clinical Psychopharmacology and Neuroscience.30;13(1),62-7.
  11. Shiina, A., Yamamoto, T., Higuchi, Y., Yamanaka, Y., Hirano, S., Asahina, M., Iyo, M.(2015) Risk Factors for Psychiatric Complications after Deep Brain Stimulation in Patients with Parkinson’s Disease: An Observational Study. Neurological Disorders.3,2.
  12. Mellsop, G., Choi, W. K., Every-Palmer, S., Green, B., Heffernan, E., Kachaeva, M., Shiina, A., Wang, X.(2015) Drug driven psychoses and Legal Responsibility or Insanity in Six Western Pacific Nations. International Journal of Law and Psychiatry (in press).
  13. Shiina, A., Iyo, M., Igarashi, Y.(2015) Defining outcome measures of hospitalization for assessment in the Japanese forensic mental health scheme: a Delphi study. International Journal of Mental Health Systems.0.379861111.
  14. Nakazato, M., Sutoh, C., Matsuzawa, D., Ishima, T., Hirano, Y., Hashimoto, T., Niitsu, T., Kanahara, N., Shiina, A., Tadokoro, S., Abe, T., Asano, K., Ishikawa, M., Shiraishi, T., Kobori, O., Shimizu, E., Iyo, M., Hashimoto, K.(2015) Decreased Serum Glutamate Levels in Women with Anorexia Nervosa and Bulimia Nervosa. The Open Nutrition Journal (in press).
  15. Shiina, A., Iyo, M., Hirata, T., Igarashi, Y.(2015) Audit study of the new hospitalization for assessment scheme for forensic mental health in japan. World Journal of Psychiatry.5(2),234-42.

原著 2014年

  1. Sasaki, T., Hashimoto, K., Tachibana, M., Kurata, T., Kimura, H., Komatsu, H., Ishikawa, M., Hasegawa, T., Shiina, A., Hashimoto, T., Kanahara, N., Shiraishi, T., Iyo, M.(2014) Tipepidine in adolescent patients with depression: a 4 week, open-label, preliminary study. Neuropsychiatric Disease and Treatment. Neuropsychiatric Disease and Treatment.10,719–22.
  2. Shiina, A., Iyo, M., Yoshizumi, A., Hirabayashi, N.(2014) Recognition of change in the reform of forensic mental health by clinical practitioners: a questionnaire survey in Japan. Annals of General Psychiatry.
  3. Imai, A., Hayashi, N., Shiina, A., Sakikawa, N., Igarashi, Y.(2014) Factors associated with violence among Japanese patients with schizophrenia prior to psychiatric emergency hospitalization: A case-controlled study. Schizophrenia Research.160,1-3,27–32.
  4. Nagata, T., Nakagawa, A., Matsumoto, S., Shina, A., Iyo, M., Hirabayashi, N., Igarashi,Y.(2014) Characteristics of Female Mentally Disordered Offenders Culpable under the New Legislation in Japan: A Gender Comparison Study. Criminal Behaviour and Mental Health.
  5. Okita, K., Kanahara, N., Nishimura, M., Yoshida, T., Yasui-Furukori, N., Niitsu, T., Yoshida, T., Ishikawa, M., Kimura, H., Nlmura, F., Iyo, M.(2014 Aug) Second-generation antipsychotics and bone turnover in schizophrenia. Schizophrenia Research.157(1-3): 137-41.
  6. Kimura H, Kanahara N, Komatsu N, Ishige M, Muneoka K, Yoshimura M, Yamanaka H, Suzuki T, Komatsu H, Sasaki T, Hashimoto T, Hasegawa T, Shiina A, Ishikawa M, Sekine Y, Shiraishi T, Watanabe H, Shimizu E, Hashimoto K, Iyo M.(2014) A prospective comparative study of risperidone long-acting injectable for treatment-resistant schizophrenia with dopamine supersensitivity psychosis. Schizophrenia Research 155. 155, 52-58.

原著 2013年

  1. Every-Palmer, S., Brink, J., Chern, T. P., Choi, W. K., Hern-Yee, J. G., Green, B., Heffernan, E., Johnson, S. B., Kachaeva, M., Shiina, A., Walker, D., Wu, K., Wang, X., Mellsop, G.(2013) Review of psychiatric services to mentally disordered offenders around the Pacific Rim. Asia Pacific Psychiatry.6(1),1-17.
  2. Kimura, H., Kanahara, N., Watanabe, H., Iyo, M. (2013) Potential treatment strategy of risperidone in long-acting injectable form for schizophrenia with dopamine supersensitivity psychosis. Schizophr. Res. 145, 130-131.
  3. Iyo M, Tadokoro S, Kanahara N, Hashimoto T, Niitsu T, Watanabe H, Hashimoto K.(2013) Optimal extent of dopamine D2 receptor occupancy by antipsychotics for treatment of dopamine supersensitivity psychosis and late-onset psychosis. J Clin Psychopharmacol. 33, 398-404.
  4. Shiina, A., Okita, K., Fujisaki, M., Igarashi, Y., Iyo, M.(2013) No change of attitude toward forensic psychiatry: 5 years after the Medical Treatment and Supervision Act in Japan. Open Journal of Psychiatry.3,203-5.
  5. Yamamoto, T., Kanahara, N., Hirai, A., Watanabe, H., Iyo, M. (2013) Lamotrigine in binge-eating disorder associated with bipolar II depression and treatment-resistant type 2 diabetes mellitus: a case report. Clinical Neuropharmacology.36, 34-35.
  6. Komatsu H, Sekine Y, Okamura N, Kanahara N, Okita K, Matsubara S, Hirata T, Komiyama T, Watanabe H, Minabe Y, Iyo M. (2013) Effectiveness of Information Technology Aided Relapse Prevention Programme in Schizophrenia excluding the effect of user adherence: a randomized controlled trial. Schizophr Res. 150, 240-244.
  7. Kanahara, N., Yoshida, T., Oda, Y., Yamanaka, H., Moriyama, H., Hayashi, H., Shibuya, T., Nagaushi, Y, Sawa, T., Sekine, Y., Shimizu, E., Asano, M., Iyo, M.(2013 Jun) Onset pattern and long-term prognosis in schizophrenia: 10-year longitudinal follow-up study. PLoS One.e67273.

原著 2012年

  1. Yoshida, T., Ishikawa, M., Niitsu, T., Nakazato, M., Watanabe, H., Shiraishi, T., Shiina, A., Hashimoto, T., Kanahara, N., Hasegawa, T., Enohara, M., Kimura, A., Iyo, M., Hashimoto, K.(2012 Aug 3.) Decreased serum levels of mature brain-derived neurotrophic factor (BDNF), but not its precursor proBDNF, in patients with major depressive disorder. PLoS One. 7(8):e42676. doi: 10.1371/journal.pone.0042676. Epub.
  2. Okita, K., Shiina, A., Shiraishi, T., Watanabe, H., Igarashi, Y., Iyo, M.(2012) The Effect of a New Educational Model on the Motivation of Novice Japanese Psychiatrists to enter Forensic Psychiatry. MedEdWorld.
  3. Arai, E., Arai, M., Uchiyama, T., Higuchi, Y., Aoyagi, K., Yamanaka, Y., Yamamoto, T., Nagano, O., Shiina, A., Maruoka, D., Matsumura, T., Nakagawa, T., Katsuno, T., Imazeki, F., Saeki, N., Kuwabara, S., Yokosuka, O.(2012) Subthalamic deep brain stimulation can improve gastric emptying in Parkinson’s disease. Brain.135(Pt 5):1478-85.
  4. Nakazato, M., Arakawa, S., Takase, M., Suzuki, M., Shiina, A., Hashimoto, T., Kanahara, N., Kimura, H., Niitsu, T., Yoshida, T., Shiraishi, T., Watanabe, H., Ishima, T., Fujita, Y., Hashimoto, K., Shimizu, E., Iyo, M. (2012) Effectiveness of enteral formula with enriched polyunsaturated fatty acids in the treatment of anorexia nervosa: a pilot open case study. The Open Nutrition.Journal 6,104-7.
  5. Niitsu, T., Fujisaki, M., Shiina, A., Yoshida, T., Hasegawa, T., Kanahara, N., Hashimoto, T., Shiraishi, T., Fukami, G., Nakazato, M., Shirayama, Y., Hashimoto, K., Iyo, M.(2012) A Randomized, Double-Blind, Placebo-Controlled Trial of Fluvoxamine in Patients With Schizophrenia. Journal of Clinical Psychopharmacology.32,5,593-601.

原著 2011年

  1. Shiina, A., Fujisaki, M., Nagata, T., Oda, Y., Suzuki, M., Yoshizawa, M., Iyo, M., Igarashi, Y. (2011) Expert Consensus on Hospitalization for Assessment: A Survey in Japan for a New Forensic Mental Health System. Annals of General Psychiatry.10:11:00
  2. Sasaki, T., Niitsu, T., Hashimoto, T., Kanahara, N., Shiina, A., Hasegawa, T., Kimura, H., Ishikawa, M., Tone, J., Yamauchi, A., Hosoda, Y., Kunou, M., Takahashi, J., Ishima, T., Fujita, Y., Nakazato, M., Hashimoto, K., Iyo, M.(2011) Decreased Levels of Serum Brain-Derived Neurotrophic Factor in Male Pediatric Patients with Depression. The Open Clinical Chemistry.Journal 4, 28-33.
  3. Haraguchi, T., Fujisaki, M., Shiina, A., Igarashi, Y., Okamura, N., Fukami, G., Shiraishi, T., Nakazato, M., Iyo, M.(2011) Attitudes of Japanese psychiatrists toward forensic mental health, as revealed by a national survey. Psychiatry Clin Neurosci.65(2):150-7.
  4. Niitsu, T., Shirayama, Y., Matsuzawa, D., Hasegawa, T., Kanahara, N., Hashimoto, T., Shiraishi, T., Shiina, A., Fukami, G., Fujisaki, M., Watanabe, H., Nakazato, M., Asano, M., Kimura, S., Hashimoto, K., Iyo, M.(2011) Associations of serum brain-derived neurotrophic factor with cognitive impairments and negative symptoms in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry.35(8):1836-40.

原著 2010年

  1. Shiina, A., Shirayama, Y., Niitsu, T., Hashimoto, T., Yoshida, T., Hasegawa, T., Haraguchi, T., Kanahara, N,, Shiraishi, T., Fujisaki, M., Fukami, G., Nakazato, M., Iyo, M., Hashimoto, K.(2010) A randomized, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia. Annals of General Psychiatry.9:27:00
  2. The adenosine A2A receptor is associated with methamphetamine dependence/psychosis in the Japanese population. Kobayashi H., Ujike H., Iwata N, Inada T., Yamada M., Sekine Y., Uchimura N., Iyo M., Ozaki N., Itokawa M., Sora I. Behav Brain Funct. 2010 Aug 30;6:50.
  3. Nakamura K., Sekine Y., Ouchi Y., Tsujii M., Yoshikawa E., Futatsubashi M., Tsuchiya K.J., Sugihara G., Iwata Y., Suzuki K., Matsuzaki H., Suda S., Sugiyama T., Takei N., Mori N. Brain serotonin and dopamine transporter bindings in adults with high-functioning autism. (2010) Arch. Gen. Psychiatry. 67, 59-68.
  4. Okamura N., Reinscheid R.K., Ohgake S., Iyo M., Hashimoto K. (2010) Neuropeptide S attenuates neuropathological, neurochemical and behavioral changes induced by the NMDA receptor antagonist MK-801. Neuropharmacology. 58, 166-172.

原著 2009年

  1. Kanahara N., Miyatake R., Sekine Y., Inada T., Ozaki N., Iwata N., Harano M., Komiyama T., Yamada M., Sora I., Ujike H., Iyo M., Hashimoto K. (2009) Association study between the PIK4CA gene and methamphetamine use disorder in a Japanese population. Am. J. Med. Genet. B Neuropsychiatr. Genet.150B,233-238.
  2. Kanahara N., Shimizu E., Sekine Y., Uchida Y., Shibuya T., Yamanaka H., Hashimoto T., Asaka T., Sasaki T., Miyatake R., Ohkamia T., Fukami G., Fujisaki M., Watanabe H., Shirayama Y., Hayashi H., Hashimoto K., Asano M., Iyo M. Does hypofrontality expand to global brain area in progression of schizophrenia? : A cross-sectional study between first-episode and chronic schizophrenia. (2009) Prog. Neuropsychopharmacol. Biol. Psychiatry. 33, 410-415.
  3. Nakamura K., Sekine Y., Takei N., Iwata Y., Suzuki K., Anitha A., Inada T., Harano M., Komiyama T., Yamada M., Iwata N., Iyo M., Sora I., Ozaki N., Ujike H., Mori N. An association study of monoamine oxidase A (MAOA) gene polymorphism in methamphetamine psychosis. (2009) Neurosci. Lett. 455, 120-123.
  4. Anitha A., Nakamura K., Yamada K., Iwayama Y., Toyota T., Takei N., Iwata Y., Suzuki K., Sekine Y., Matsuzaki H., Kawai M., Thanseem I., Miyoshi K., Katayama T., Matsuzaki S., Baba K., Honda A., Hattori T., Shimizu S., Kumamoto N., Kikuchi M., Tohyama M., Yoshikawa T., Mori N. Association studies and gene expression analyses of the DISC1-interacting molecules, pericentrin 2 (PCNT2) and DISC1-binding zinc finger protein (DBZ), with schizophrenia and with bipolar disorder. (in press) Am. J. Med. Genet. B. Neuropsychiatr. Genet.
  5. Nakamura K., Sekine Y., Ouchi Y., Tsujii M., Yoshikawa E., Futatsubashi M., Tsuchiya K.J., Sugihara G., Takebayashi K., Iwata Y., Suzuki K., Suda S., Matsuzaki H., Sugiyama T., Takei N., Mori N. (in press) Brain serotonin and dopamine transporter bindings in adults with high-functioning autism. Arch. Gen. Psychiatry.
  6. Duangdao D.M., Clark S.D., Okamura N., Reinscheid R.K. (2009) Behavioral phenotyping of neuropeptide S receptor knockout mice. Behav Brain Res. 205, 1-9.
  7. Ohgake S., Shimizu E., Hashimoto K., Okamura N., Koike K., Koizumi H., Fujisaki M., Kanahara N., Matsuda S., Sutoh C., Matsuzawa D., Muramatsu H., Muramatsu T., Iyo M. (2009) Dopaminergic hypofunctions and prepulse inhibition deficits in mice lacking midkine. Prog Neuropsychopharmacol Biol Psychiatry. 33, 541-546.

原著 2008年

  1. Kishimoto M., Ujike H., Motohashi Y., Tanaka Y., Okahisa Y., Kotaka T., Harano M., Inada T., Yamada M., Komiyama T., Hori T., Sekine Y., Iwata N., Sora I., Iyo M., Ozaki N., Kuroda S. (2008) The dysbindin gene (DTNBP1) is associated with methamphetamine psychosis. Biol. Psychiatry. 63.191-196.
  2. Otani K., Ujike H., Sakai A., Okahisa Y., Kotaka T., Inada T., Harano M., Komiyama T., Hori T., Yamada M., Sekine Y., Iwata N., Iyo M., Sora I., Ozaki N., Kuroda S. (2008) Reduced CYP2D6 activity is a negative risk factor for methamphetamine dependence. Neurosci. Lett. 434, 88-92.
  3. Suzuki K., Nakamura K., Iwata Y., Sekine Y., Kawai M., Sugihara G., Tsuchiya K.J., Suda S., Matsuzaki H., Takei N., Hashimoto K., Mori N. (2008) Decreased expression of reelin receptor VLDLR in peripheral lymphocytes of drug-naive schizophrenic patients. Schizophr. Res. 98, 148-156.
  4. Anitha A., Nakamura K., Yamada K., Iwayama Y., Toyota T., Takei N., Iwata Y., Suzuki K., Sekine Y., Matsuzaki H., Kawai M., Miyoshi K., Katayama T., Matsuzaki S., Baba K., Honda A., Hattori T., Shimizu S., Kumamoto N., Tohyama M., Yoshikawa T., Mori N. (2008) Gene and expression analyses reveal enhanced expression of pericentrin 2 (PCNT2) in bipolar disorder. Biol. Psychiatry 63, 678-685.
  5. Tsuchiya K.J., Matsumoto K., Miyachi T., Tsujii M., Nakamura K., Takagai S., Kawai M., Yagi A., Iwaki K., Suda S., Sugihara G., Iwata Y., Matsuzaki H., Sekine Y., Suzuki K., Sugiyama T., Mori N., Takei N. (2008) Serum levels of P-selectin in men with high-functioning autism. Br. J. Psychiatry. 193:316-321.
  6. Iwata Y., Tsuchiya K.J., Mikawa S., Nakamura K., Takai Y., Suda S., Sekine Y., Suzuki K., Kawai M., Sugihara G., Matsuzaki H., Hashimoto K., Tsujii M., Sugiyama T., Takei N., Mori N. (2008) Decreased serum levels of soluble P-selectin in patients with high-functioning autism were correlated negatively with abnormal social development in early life and positively with head circumference at birth. Br. J. Psychiatry. 193, 338-339.
  7. Hashimoto T., Hashimoto K., Miyatake R., Matsuzawa D., Sekine Y., Inada T., Ozaki N., Iwata N., Harano M., Komiyama T., Yamada M., Sora I., Ujike H., Iyo M. (2008) Association study between polymorphisms in glutathione-related genes and methamphetamine use disorder in a Japanese population. Am. J. Med. Genet. B Neuropsychiatr. Genet. 147B:1040-1046.
  8. Uhl G.R., Drgon T., Liu Q.R., Johnson C., Walther D., Ujike H., Komiyama T., Harano M., Sekine Y., Inada T., Ozaki N., Iyo M., Iwata N., Yamada M., Sora I., Chen C.K., Liu H.C., Lin S.K. (2008) Genome-wide association for methamphetamine dependence. Convergent results from two samples. Arch. Gen. Psychiatry. 65, 345-355.
  9. Sekine Y., Ouchi Y., Sugihara G., Takei N., Yoshikawa E., Nakamura K., Iwata Y., Tsuchiya K.J., Suda S., Suzuki K., Kawai M., Takebayashi K., Yamamoto S., Matsuzaki H., Ueki T., Mori N., Gold M.S., Cadet J.L. (2008) Methamphetamine causes microglial activation in the brains of human abusers. J. Neurosci. 28, 5756-5761.
  10. Nakamura K., Anitha A., Yamada K., Tsujii M., Iwayama Y., Hattori E., Toyota T., Suda S., Takei N., Iwata Y., Suzuki K., Matsuzaki H., Kawai M., Sekine Y., Tsuchiya K.J., Sugihara G.I., Ouchi Y., Sugiyama T., Yoshikawa T. Mori N. (2008) Genetic and expression analyses reveal elevated expression of syntaxin 1A (STX1A) in high functioning autism. Int. J. Neuropsychopharmacol. 11:1073-1084.
  11. Kotaka T., Ujike H., Morita Y., Kishimoto M., Okahisa Y., Inada T., Harano M., Komiyama T., Hori T., Yamada M., Sekine Y., Iwata N., Iyo M., Sora I., Ozaki N., Kuroda S. (2008) Association study between casein kinase 1 epsilon gene and methamphetamine dependence. Ann. N. Y. Acad. Sci. 1139:43-48.
  12. Ezaki N., Nakamura K., Sekine Y., Thanseem I., Anitha A., Iwata Y., Kawai M., Takebayashi K., Suzuki K., Takei N., Iyo M., Inada T., Iwata N., Harano M., Komiyama T., Yamada M., Sora I., Ujike H., Mori N. (2008) Short allele of 5-HTTLPR as a risk factor for the development of psychosis in Japanese methamphetamine abusers. Ann. N. Y. Acad. Sci. 1139:49-56.
  13. Kinoshita Y., Ikeda M., Ujike H., Kitajima T., Yamanouchi Y., Aleksic B., Kishi T., Kawashima K., Ohkouchi T., Ozaki N., Inada T., Harano M., Komiyama T., Hori T., Yamada M., Sekine Y., Iyo M., Sora I., Iwata N. (2008) Association study of the calcineurin A g subunit gene (PPP3CC) and methamphetamine-use disorder in a Japanese population. Ann. N. Y. Acad. Sci. 1139:57-62.
  14. Kishi T., Ikeda M., Kitajima T., Yamanouchi Y., Kinoshita Y., Kawashima K., Inada T., Harano M., Komiyama T., Hori T., Yamada M., Iyo M., Sora I., Sekine Y., Ozaki N., Ujike H., Iwata N. (2008) Glutamate cysteine ligase modifier (GCLM) subunit gene is not associated with methamphetamine-use disorder or schizophrenia in the Japanese population. Ann. N. Y. Acad. Sci. 1139:63-69.
  15. Kishi T., Ikeda M., Kitajima T., Yamanouchi Y., Kinoshita Y., Kawashima K., Inada T., Harano M., Komiyama T., Hori T., Yamada M., Iyo M., Sora I., Sekine Y., Ozaki N., Ujike H., Iwata N. a4 and b2 subunits of neuronal nicotinic acetylcholine receptor genes are not associated with methamphetamine-use disorder in the Japanese population. (2008) Ann. N. Y. Acad. Sci. 1139:70-82.
  16. Kishi T., Ikeda M., Kitajima T., Yamanouchi Y., Kinoshita Y., Kawashima K., Inada T., Harano M., Komiyama T., Hori T., Yamada M., Iyo M. Sora I., Sekine Y., Ozaki N., Ujike H., Iwata N. (2008) Prostate apoptosis response 4 gene is not associated with methamphetamine-use disorder in the Japanese population. (2008) Ann. N. Y. Acad. Sci. 1139:83-88.
  17. Iwata Y., Tsuchiya K.J., Mikawa S., Nakamura K., Takai Y., Suda S., Sekine Y., Suzuki K., Kawai M., Sugihara G., Matsuzaki H., Hashimoto K., Tsujii M., Sugiyama T., Takei N., Mori N. Serum levels of P-selectin in men with high-functioning autism. (2008) Br. J. Psychiatry. 193, 338-339.
  18. Jungling K., Seidenbecher T., Sosulina L., Lesting J., Sangha S., Clark S.D., Okamura N., Duangdao D.M., Xu Y.L., Reinscheid R.K., Pape H.C. (2008) Neuropeptide S-mediated control of fear expression and extinction: role of intercalated GABAergic neurons in the amygdala. Neuron. 59, 298-310.
  19. Mohanty S.K., Reinscheid R.K., Liu X., Okamura N., Krasieva T.B., Berns M.W. (2008) In-depth activation of channelrhodopsin 2-sensitized excitable cells with high spatial resolution using two-photon excitation with a near-infrared laser microbeam. Biophys J. 95, 3916-3926.
  20. Okamura N., Habay S.A., Zeng J., Chamberlin A.R., Reinscheid R.K. (2008) Synthesis and pharmacological in vitro and in vivo profile of 3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide (SHA 68), a selective antagonist of the neuropeptide S receptor. J Pharmacol Exp Ther. 325, 893-901.

原著 2007年

  1. Ikeda M., Ozaki N., Suzuki T., Kitajima T., Yamanouchi Y., Kinoshita Y., Kishi T., Sekine Y., Iyo M., Harano M., Komiyama T., Yamada M., Sora I., Ujike H., Inada T., Iwata N. (2007) Possible association of beta-arrestin 2 gene with methamphetamine use disorder, but not schizophrenia. Genes. Brain. Behav. 6, 107-112.
  2. Okada K., Hashimoto K., Iwata Y., Nakamura K., Tsujii M., Tsuchiya K.J., Sekine Y., Suda S., Suzuki K., Sugihara G., Matsuzaki H., Sugiyama T., Kawai M., Minabe Y., Takei N., Mori N. (2007) Decreased serum levels of transforming growth factor- b1 in patients with autism. Prog. Neuropsychopharmacol. Biol. Psychiatry 31, 187-190.
  3. Nishimura K., Nakamura K., Anitha A., Yamada K., Tsujii M., Iwayama Y., Hattori E., Toyota T., Takei N., Miyachi T., Iwata Y., Suzuki K., Matsuzaki H., Kawai M., Sekine Y., Tsuchiya K., Sugihara G., Suda S., Ouchi Y., Sugiyama T., Yoshikawa T., Mori N. (2007) Genetic analyses of the brain-derived neurotrophic factor (BDNF) gene in autism. Biochem. Biophys. Res. Commun. 356, 200-206.
  4. Iwata Y., Suzuki K., Nakamura K., Matsuzaki H., Sekine Y., Tsuchiya K.J., Sugihara G., Kawai M., Minabe Y., Takei N., Mori N. (2007) Increased levels of serum soluble L-selectin in unmedicated patients with schizophrenia.Schizophr. Res. 89, 154-160.
  5. Iwata Y., Nakajima M., Yamada K., Nakamura K., Sekine Y., Tsuchiya K.J., Sugihara G., Matsuzaki H., Suda S., Suzuki K., Takei N., Mori N., Iwayama Y., Takao H., Yoshikawa T., Riley B., Makoff A., Sham P., Chen R., Collier D. (2007) Linkage disequilibrium analysis of the CHRNA7 gene and its partially duplicated region in schizophrenia. Neurosci. Res. 57, 194-202.
  6. Sugihara G., Hashimoto K., Iwata Y., Nakamura K., Tsujii M., Tsuchiya K.J., Sekine Y., Suzuki K., Suda S., Matsuzaki H., Kawai M., Minabe Y., Yagi A., Takei N., Sugiyama T., Mori N. (2007) Decreased serum levels of hepatocyte growth factor in male adults with high-functioning autism. Prog. Neuropsychopharmacol. Biol. Psychiatry. 31, 412-415.
  7. Sekine Y., Suzuki K., Ramachandran P.V., Blackburn T.P., Ashby C.R. Jr. (2007) Acute and repeated administration of fluoxetine, citalopram, and paroxetine significantly alters the activity of midbrain dopamine neurons in rats. An in vivo electrophysiological study. Synapse 61, 72-77.
  8. Suzuki K., Hashimoto K., Iwata Y., Nakamura K., Tsujii M., Tsuchiya K.J., Sekine Y., Suda S., Sugihara G., Matsuzaki H., Sugiyama T., Kawai M., Minabe Y., Takei N., Mori N. (2007) Decreased serum levels of epidermal growth factor in adult subjects with high-functioning autism. Biol. Psychiatry. 62, 267-269.
  9. Matsuzaki H., Minabe Y., Nakamura K., Suzuki K., Iwata Y., Sekine Y., Tsuchiya K.J., Sugihara G., Suda S., Takei N., Nakahara D., Hashimoto K., Nairn A.C., Mori N., Sato K. (2007) Disruption of reelin signaling attenuates methamphetamine-induced hyperlocomotion. Eur. J. Neurosci. 25, 3376-3384.
  10. Matsuzawa D., Hashimoto K., Miyatake R., Shirayama Y., Shimizu E., Maeda K., Suzuki Y., Mashimo Y., Sekine Y., Inada T., Ozaki N., Iwata N., Harano M., Komiyama T., Yamada M., Sora I., Ujike H., Hata A., Sawa A., Iyo M. (2007) Identification of functional polymorphisms in the promoter region of the human PICK1 gene and their association with methamphetamine psychosis. Am. J. Psychiatry. 164, 1105-1114.
  11. Toyoda T., Nakamura K., Yamada K., Thanseem I., Anitha A., Suda S., Tsujii M., Iwayama Y., Hattori E., Toyota T., Miyachi T., Iwata Y, Suzuki K, Matsuzaki H., Kawai M, Sekine Y., Tsuchiya K., Sugihara G., Ouchi Y., Sugiyama T., Takei N., Yoshikawa T., Mori N. (2007) SNP analyses of growth factor genes EGF, TGFb-1, and HGF reveal haplotypic association of EGF with autism. Biochem. Biophys. Res. Commun. 360, 715-720.
  12. Tsuchiya K.J., Hashimoto K., Iwata Y., Tsujii M., Sekine Y., Sugihara G., Matsuzaki H., Suda S., Kawai M., Nakamura K., Minabe Y., Yagi A., Iyo M., Takei N., Mori N. (2007) Decreased serum levels of PECAM-1 in subjects with high-functioning autism. A negative correlation with head circumference at birth. Biol. Psychiatry. 62, 1056-1058.
  13. Okamura N., Hashimoto K., Iyo M., Shimizu E., Dempfle A., Friedel S., Reinscheid R.K. (2007) Gender-specific association of a functional coding polymorphism in the Neuropeptide S receptor gene with panic disorder but not with schizophrenia or attention-deficit/hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry. 31, 1444-1448.
  14. Okamura N.,Reinscheid R.K. (2007) Neuropeptide S: A novel modulator of stress and arousal. Stress. 10, 221-226.
  15. Shimizu E., Hashimoto K., Ochi S., Fukami G., Fujisaki M., Koike K., Okamura N., Ohgake S., Koizumi H., Matsuzawa D., Zhang L., Watanabe H., Nakazato M., Shinoda N., Komatsu N., Morita F., Iyo M. (2007) Posterior cingulate gyrus metabolic changes in chronic schizophrenia with generalized cognitive deficits. J Psychiatr Res. 41, 49-56.

原著 2006年

  1. Ikeda M., Iwata N., Suzuki T., Kitajima T., Yamanouchi Y., Kinoshiya Y., Sekine Y., Iyo M., Harano M., Komiyama T., Yamada M., Sora I., Ujike H., Inada T., Ozaki N. (2006) Positive association of AKT1 haplotype to Japanese methamphetamine use disorder. Int. J. Neuropsychopharmacol. 9, 77-81.
  2. Sekine Y., Ouchi Y., Takei N., Yoshikawa E., Nakamura K., Futatsubashi M., Okada H., Minabe Y., Suzuki K., Iwata Y., Tsuchiya K.J., Tsukada H., Iyo M., Mori N. (2006) Brain serotonin transporter density and aggression in abstinent methamphetamine abusers. Arch. Gen. Psychiatry. 63, 90-100.
  3. Nomura A., Ujike H., Tanaka Y., Otani K., Morita Y., Kishimoto M., Morio A., Harano M., Inada T., Yamada M., Komiyama T., Sekine Y., Iwata N., Sora I., Iyo M., Ozaki N., Kuroda S. (2006) Genetic variant of prodynorphin gene is risk factor for methamphetamine dependence. Neurosci. Lett. 400, 158-162.
  4. Nakamura K., Chen C.K., Sekine Y., Iwata Y., Anitha A., Loh el-W., Takei N., Suzuki A., Kawai M., Takebayashi K., Suzuki K., Minabe Y., Tsuchiya K., Yamada K., Iyo M., Ozaki N., Inada T., Iwata N., Harano M., Komiyama T., Yamada M., Sora I., Ujike H., Ball D.M., Yoshikawa T., Lin S.K., Mori N. (2006) Association analysis of SOD2 variants with methamphetamine psychosis in Japanese and Taiwanese populations. Hum. Genet. 120, 243-252.
  5. Yoshitsugu K., Yamada K., Toyota T., Aoki-Suzuki M., Minabe Y., Nakamura K., Sekine Y., Suzuki K., Takei N., Itokawa M., Mori N., Yoshikawa T. (2006) A novel scale including strabismus and 'cuspidal ear' for distinguishing schizophrenia patients from controls using minor physical anomalies. Psychiatry Res. 145, 249-258.
  6. Ide S., Kobayashi H., Ujike H., Ozaki N.,Sekine Y., Inada T., Harano M., Komiyama T., Yamada M., Iyo M., Iwata N., Tanaka K., Shen H., Iwahashi K., Itokawa M., Minami M., Satoh M., Ikeda K., Sora I. (2006) Linkage disequilibrium and association with methamphetamine dependence/psychosis of m-opioid receptor gene polymorphisms. Pharmacogenomics J. 6, 179-188.
  7. Nakamura K., Yamada K., Iwayama Y., Toyota T., Furukawa A., Takimoto T., Terayama H., Iwahashi K., Takei N., Minabe Y., Sekine Y., Suzuki K., Iwata Y., Pillai A., Nakamoto Y., Ikeda K., Yoshii M., Fukunishi I., Yoshikawa T., Mori N. (2006) Evidence that variation in the peripheral benzodiazepine receptor (PBR) gene influences susceptibility to panic disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 141, 222-226.
  8. Suzuki A., Nakamura K., Sekine Y., Minabe Y., Takei N., Suzuki K., Iwata Y., Kawai M., Takebayashi K., Matsuzaki H., Iyo M., Ozaki N., Inada T., Iwata N., Harano M., Komiyama T., Yamada M., Sora I., Ujike H., Mori N. (2006) An association study between catechol-O-methyl transferase gene polymorphism and methamphetamine psychotic disorder. Psychiatr. Genet.16, 133-138.
  9. Sekine Y., Ouchi Y., Takei N., Yoshikawa E., Okada H., Minabe Y., Nakamura K., Suzuki K., Iwata Y., Tsuchiya K.J., Sugihara G., Mori N. (2006) Perospirone is a new generation antipsychotic. Evidence from a positron emission tomography study of serotonin 2 and D2 receptor occupancy in the living human brain. J. Clin. Psychopharmacol. 26, 531-533.
  10. Kobayashi H., Hata H., Ujike H., Harano M., Inada T., Komiyama T., Yamada M., Sekine Y., Iwata N., Iyo M., Ozaki N., Itokawa M., Naka M., Ide S., Ikeda K., Numachi Y., Sora I. (2006) Association analysis of d-opioid receptor gene polymorphisms in methamphetamine dependence/psychosis. Am. J. Med. Genet. B Neuropsychiatr. Genet. 141, 482-486.
  11. Shinohe A., Hashimoto K., Nakamura K., Tsujii M., Iwata Y., Tsuchiya K.J., Sekine Y., Suda S., Suzuki K., Sugihara G., Matsuzaki H., Minabe Y., Sugiyama T., Kawai M., Iyo M., Takei N., Mori N. Increased serum levels of glutamate in adult patients with autism. (2006) Prog. Neuropsychopharmacol. Biol. Psychiatry. 30, 1472-1477.
  12. Aoyama N., Takahashi N., Kitaichi K., Ishihara R., Saito S., Maeno N., Ji X., Takagi K., Sekine Y., Iyo M., Harano M., Komiyama T., Yamada M., Sora I., Ujike H., Iwata N., Inada T., Ozaki N. (2006) Association between gene polymorphisms of SLC22A3 and methamphetamine use disorder. Alcohol Clin. Exp. Res. 30, 1644-1649.
  13. Ujike H., Sakai A., Nakata K., Tanaka Y., Kodaka T., Okahisa Y., Harano M., Inada T., Yamada M., Komiyama T., Hori T., Sekine Y., Iwata N., Sora I., Iyo M., Ozaki N., Kuroda S. (2006) Association study of the dihydropyrimidinase-related protein 2 gene and methamphetamine psychosis. Ann. N. Y. Acad. Sci. 1074, 90-96.
  14. Nomura A., Ujike H., Tanaka Y., Kishimoto M., Otani K., Morita Y., Morio A., Harano M., Inada T., Yamada M., Komiyama T., Hori T., Sekine Y., Iwata N., Sora I., Iyo M., Ozaki N., Kuroda S. (2006) Association study of the tumor necrosis factor-alpha gene and its 1A receptor gene with methamphetamine dependence. Ann. N. Y. Acad. Sci. 1074, 116-124.
  15. Morio A., Ujike H., Nomura A., Tanaka Y., Morita Y., Otani K., Kishimoto M., Harano M., Inada T., Komiyama T., Yamada M., Sekine Y., Iwata N., Iyo M., Sora I., Ozaki N., Kuroda S. (2006) No association between CART (cocaine-and amphetamine-regulated transcript) gene and methamphetamine dependence. Ann. N. Y. Acad. Sci. 1074, 411-417.
  16. Hashimoto K., Iwata Y., Nakamura K., Tsujii M., Tsuchiya K.J., Sekine Y., Suzuki K., Minabe Y., Takei N., Iyo M., Mori N. Reduced serum levels of brain-derived neurotrophic factor in adult male patients with autism. (2006) Reduced serum levels of brain-derived neurotrophic factor in adult male patients with autism. Prog. Neuropsychopharmacol. Biol. Psychiatry. 30, 1529-1531.
  17. Shimizu E., Hashimoto K., Ohgake S., Koizumi H., Okamura N., Koike K., Fujisaki M., Iyo M. (2006) Association between angiotensin I-converting enzyme insertion/deletion gene functional polymorphism and novelty seeking personality in healthy females. Prog Neuropsychopharmacol Biol Psychiatry. 30, 99-103.

原著 2005年

  1. Shiina,A., Nakazato,M., Mitsumori,M., Koizumi,H., Shimizu,E., Fujisaki,M. Iyo,M. (2005)An open trial of outpatient group therapy for bulimic disorders: Combination program of cognitive behavioral therapy with assertive training and self-esteem enhancement.Psychiatry Clin Neurosci.59,690-6.
  2. Ouchi Y., Yoshikawa E., Kanno T., Futatsubashi M., Sekine Y., Okada H., Torizuka T., Tanaka K. (2005) Orthostatic posture affects brain hemodynamics and metabolism in cerebrovascular disease patients with and without coronary artery disease. A positron emission tomography study. Neuroimage. 24, 70-81.
  3. Itoh K., Hashimoto K., Shimizu E., Sekine Y., Ozaki N., Inada T., Harano M., Iwata N., Komiyama T., Yamada M., Sora I., Nakata K., Ujike H., Iyo M. (2005) Association study between brain-derived neurotrophic factor gene polymorphisms and methamphetamine abusers in Japan. Am. J. Med. Genet. B Neuropsychiatr. Genet. 132, 70-73.
  4. Hashimoto T., Hashimoto K., Matsuzawa D., Shimizu E., Sekine Y., Inada T., Ozaki N., Iwata N., Harano M., Komiyama T., Yamada M., Sora I., Ujike H., Iyo M. (2005) A functional glutathione S-transferase P1 gene polymorphism is associated with methamphetamine-induced psychosis in Japanese population. Am. J. Med. Genet. B Neuropsychiatr. Genet. 135, 5-9.
  5. Morita Y., Ujike H., Tanaka Y., Uchida N., Nomura A., Otani K., Kishimoto M., Morio A., Inada T., Harano M., Komiyama T., Yamada M., Sekine Y., Iwata N., Iyo M., Sora I., Ozaki N (2005). The X-box binding protein 1 (XBP1) gene is not associated with methamphetamine dependence. Neurosci. Lett. 383, 194-198.
  6. Ouchi Y., Yoshikawa E., Sekine Y., Futatsubashi M., Kanno T., Ogusu T., Torizuka T. (2005) Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann. Neurol. 57, 168-175.
  7. Nishiyama T., Ikeda M., Iwata N., Suzuki T., Kitajima T., Yamanouchi Y., Sekine Y., Iyo M., Harano M., Komiyama T., Yamada M., Sora I., Ujike H., Inada T., Furukawa T., Ozaki N. (2005) Haplotype association between GABAA receptor g 2 subunit gene (GABRG2) and methamphetamine use disorder. Pharmacogenomics J. 5, 89-95.
  8. Ohgake S., Hashimoto K., Shimizu E., Koizumi H., Okamura N., Koike K., Matsuzawa D., Sekine Y., Inada T., Ozaki N., Iwata N., Harano M., Komiyama T., Yamada M., Sora I., Ujike H., Shirayama Y., Iyo M. (2005) Functional polymorphism of the NQO2 gene is associated with methamphetamine psychosis. Addict. Biol. 10, 145-148.
  9. Morita Y., Ujike H., Tanaka Y., Uchida N., Nomura A., Ohtani K., Kishimoto M., Morio A., Imamura T., Sakai A., Inada T., Harano M., Komiyama T., Yamada M., Sekine Y., Iwata N., Iyo M., Sora I., Ozaki N., Kuroda S. A nonsynonymous polymorphism in the human fatty acid amide hydrolase gene did not associate with either methamphetamine dependence or schizophrenia. (2005) Neurosci. Lett. 376, 182-187.
  10. Kobayashi K., Shimizu E., Hashimoto K., Mitsumori M., Koike K., Okamura N., Koizumi H., Ohgake S., Matsuzawa D., Zhang L., Nakazato M., Iyo M. (2005) Serum brain-derived neurotrophic factor (BDNF) levels in patients with panic disorder: as a biological predictor of response to group cognitive behavioral therapy. Prog Neuropsychopharmacol Biol Psychiatry. 29, 658-663.
  11. Koike K., Hashimoto K., Fukami G., Okamura N., Zhang L., Ohgake S., Koizumi H., Matsuzawa D., Kawamura N., Shimizu E., Iyo M. (2005) The immunophilin ligand FK506 protects against methamphetamine-induced dopaminergic neurotoxicity in mouse striatum. Neuropharmacology. 48, 391-397.
  12. Koike K., Hashimoto K., Takai N., Shimizu E., Komatsu N., Watanabe H., Nakazato M., Okamura N., Stevens K.E., Freedman R., Iyo M. (2005) Tropisetron improves deficits in auditory P50 suppression in schizophrenia. Schizophr Res. 76, 67-72.
  13. Ohgake S., Hashimoto K., Shimizu E., Koizumi H., Okamura N., Koike K., Matsuzawa D., Sekine Y., Inada T., Ozaki N., Iwata N., Harano M., Komiyama T., Yamada M., Sora I., Ujike H., Shirayama Y., Iyo M. (2005) Functional polymorphism of the NQO2 gene is associated with methamphetamine psychosis. Addict Biol. 10, 145-148.
  14. Reinscheid R.K., Xu Y.L., Okamura N., Zeng J., Chung S., Pai R., Wang Z., Civelli O. (2005) Pharmacological characterization of human and murine neuropeptide s receptor variants. J Pharmacol Exp Ther. 315, 1338-1345.
  15. Salama R.H., Muramatsu H., Shimizu E., Hashimoto K., Ohgake S., Watanabe H., Komatsu N., Okamura N., Koike K., Shinoda N., Okada S., Iyo M., Muramatsu T. (2005) Increased midkine levels in sera from patients with Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry. 29, 611-616.
  16. Shimizu E., Hashimoto K., Koizumi H., Kobayashi K., Itoh K., Mitsumori M., Ohgake S., Okamura N., Koike K., Matsuzawa D., Zhang L., Kumakiri C., Nakazato M., Komatsu N., Iyo M. (2005) No association of the brain-derived neurotrophic factor (BDNF) gene polymorphisms with panic disorder. Prog Neuropsychopharmacol Biol Psychiatry. 29, 708-712.

原著 2004年

  1. Nakazato, M., Hashimoto, K., Shiina, A., Koizumi, H., Mitsumoti, M., Imai, M., Shimizu, E., Iyo, M.(2004)No changes in serum ghrelin levels in female patients with bulimia nervosa.Prog Neuropsychopharmacol Biol Psychiatry.28(7):1181-4.
  2. Tani K., Takei N., Kawai M., Suzuki K., Sekine Y., Toyoda T., Minabe Y., Mori N. (2004) Augmentation of milnacipran by risperidone in treatment for major depression. Int. J. Neuropsychopharmacol. 7, 1-4.
  3. Koizumi H., Hashimoto K., Kumakiri C., Shimizu E., Sekine Y., Ozaki N., Inada T., Harano M., Komiyama T., Yamada M., Sora I., Ujike H., Takei N., Iyo M. (2004) Association between the glutathione S-transferase M1 genedeletion and female methamphetamine abusers. Am. J. Med. Genet. B Neuropsychiatr. Genet. 126, 43-45.
  4. Sekizawa T., Iwata Y., Nakamura K., Matsumoto H., Suzuki A., Suzuki K., Sekine Y., Takei N., Minabe Y., Mori N. Childhood-onset schizophrenia and tryptophan hydroxylase gene polymorphism. (2004) Am. J. Med. Genet. B Neuropsychiatr. Genet. 132, 70-73.
  5. Suzuki K., Takei N., Iwata Y., Sekine Y., Toyoda T., Nakamura K., Minabe Y., Kawai M., Iyo M., Mori N. (2004) Do olfactory reference syndrome and Jiko-shu-kyofu (a subtype of Taijin-kyofu) share a common entity? Acta. Psychiatr. Scand. 109, 150-155.
  6. Toyota T., Yoshitsugu K., Ebihara M., Yamada K., Ohba H., Fukasawa M., Minabe Y., Nakamura K., Sekine Y., Takei N., Suzuki K., Itokawa M., Meerabux J.M., Iwayama-Shigeno Y., Tomaru Y., Shimizu H., Hattori E., Mori N., Yoshikawa T. (2004) Association between schizophrenia with ocular misalignment and polyalanine length variation in PMX2B. Hum. Mol. Genet. 13, 551-561.
  7. Takebayashi K., Sekine Y., Takei N., Minabe Y., Isoda H., Takeda H., Nishimura K., Nakamura K., Suzuki K., Iwata Y., Sakahara H., Mori N. (2004) Metabolite alterations in basal ganglia associated with psychiatric symptoms of abstinent toluene users. A proton MRS study. Neuropsychopharmacology. 29, 1019-1026.
  8. Yamada K., Nakamura K., Minabe Y., Iwayama-Shigeno Y., Takao H., Toyota T., Hattori E., Takei N., Sekine Y., Suzuki K., Iwata Y., Miyoshi K., Honda A., Baba K., Katayama T., Tohyama M., Mori N., Yoshikawa T. (2004) Association analysis of FEZ1 variants with schizophrenia in Japanese cohorts. Biol. Psychiatry. 56, 683-690.
  9. Inada T., Iijima Y., Uchida N., Maeda T., Iwashita S., Ozaki N., Harano M., Komiyama T., Yamada M., Sekine Y., Iyo M., Sora I., Ujike H. (2004) No association found between the type 1 s receptor gene polymorphisms and methamphetamine abuse in the Japanese population. a collaborative study by the Japanese genetic initiative for drug abuse. Ann. N. Y. Acad. Sci. 1025, 27-33.
  10. Iwata N., Inada T., Harano M., Komiyama T., Yamada M., Sekine Y., Iyo M., Sora I., Ujike H., Ozaki N. (2004) No association is found between the candidate genes of t-PA/plasminogen system and Japanese methamphetamine-related disorder. a collaborative study by the Japanese genetic initiative for drug abuse. Ann. N. Y. Acad. Sci. 1025, 34-38.
  11. Iyo M., Sekine Y., Mori N. (2004) Neuromechanism of developing methamphetamine psychosis. A neuroimaging study. Ann. N. Y. Acad. Sci. 1025, 288-295.
  12. Harano M., Uchimura N., Abe H., Ishibashi M., Iida N., Yanagimoto K., Tanaka T., Maeda H., Sora I., Iyo M., Komiyama T., Yamada M., Sekine Y., Inada T., Ozaki N., Ujike H. (2004) A polymorphism of DRD2 gene and brain atrophy in methamphetamine psychosis. Ann. N. Y. Acad. Sci. 1025, 307-315.
  13. Ide S., Kobayashi H., Tanaka K., Ujike H., Sekine Y., Ozaki N., Inada T., Harano M., Komiyama T., Yamada M., Iyo M., Ikeda K., Sora I. (2004) Gene polymorphisms of the m opioid receptor in methamphetamine abusers. Ann. N. Y. Acad. Sci. 1025, 316-324.
  14. Kobayashi H., Ide S., Hasegawa J., Ujike H., Sekine Y., Ozaki N., Inada T., Harano M., Komiyama T., Yamada M., Iyo M., Shen H.W., Ikeda K., Sora I. (2004) Study of association a-synuclein gene polymorphism and methamphetamine psychosis/dependence. Ann. N. Y. Acad. Sci. 1025, 325-334.
  15. Fukami G., Hashimoto K., Koike K., Okamura N., Shimizu E., Iyo M. (2004) Effect of antioxidant N-acetyl-L-cysteine on behavioral changes and neurotoxicity in rats after administration of methamphetamine. Brain Res. 1016, 90-95.
  16. Hashimoto K., Fukushima T., Shimizu E., Okada S., Komatsu N., Okamura N., Koike K., Koizumi H., Kumakiri C., Imai K., Iyo M. (2004) Possible role of D-serine in the pathophysiology of Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry. 28, 385-388.
  17. Hashimoto K., Okamura N., Shimizu E., Iyo M. (2004) Glutamate hypothesis of schizophrenia and approach for possible therapeutic drugs. Curr Med Chem - CNS Agents. 4, 147-154.
  18. Koike K., Hashimoto K., Okamura N., Ohgake S., Shimizu E., Koizumi H., Komatsu N., Iyo M. (2004) Decreased cell proliferation in the dentate gyrus of alpha 7 nicotinic acetylcholine receptor heterozygous mice. Prog Neuropsychopharmacol Biol Psychiatry. 28, 517-520.
  19. Koizumi H., Hashimoto K., Itoh K., Nakazato M., Shimizu E., Ohgake S., Koike K., Okamura N., Matsushita S., Suzuki K., Murayama M., Higuchi S., Iyo M. (2004) Association between the brain-derived neurotrophic factor 196G/A polymorphism and eating disorders. Am J Med Genet. 127B, 125-127.
  20. Okamura N., Hashimoto K., Shimizu E., Kumakiri C., Komatsu N., Iyo M. (2004) Adenosine A1 receptor agonists block the neuropathological changes in rat retrosplenial cortex after administration of the NMDA receptor antagonist dizocilpine. Neuropsychopharmacology. 29, 544-550.
  21. Shimizu E., Hashimoto K., Kobayashi K., Mitsumori M., Ohgake S., Koizumi H., Okamura N., Koike K., Kumakiri C., Nakazato M., Komatsu N., Iyo M. (2004) Lack of association between angiotensin I-converting enzyme insertion/deletion gene functional polymorphism and panic disorder in humans. Neurosci Lett. 363, 81-83.

原著 2003年

  1. Iwata Y., Matsumoto H., Minabe Y., Osada N., Nakamura K., Sekizawa T., Suzuki K., Sekine Y., Takei N., Mori N. (2003) Early-onset schizophrenia and dopamine-related gene polymorphism. Am. J. Med. Genet. B Neuropsychiatr. Genet. 116, 23-26.
  2. Nakamura K., Iwahashi K., Ameno K., Sekine Y., Suzuki K., Minabe Y., Mori N. (2003) CYP2E1 and clinical features in alcoholics. Neuropsychobiology. 47, 86-89.
  3. Won M., Minabe Y., Tani K., Suzuki K., Kawai M., Sekine Y., Ashby C.R. Jr., Takei N., Mori N (2003). The effects of dentate granule cell destruction on behavioral activity and Fos protein expression induced by systemic MDMA in rats. Neurosci. Res. 46,153-160.
  4. Ujike H., Harano M., Inada T., Yamada M., Komiyama T., Sekine Y., Sora I., Iyo M., Katsu T., Nomura A., Nakata K., Ozaki N. (2003) Nine- or fewer repeat alleles in VNTR polymorphism of the dopamine transporter gene is a strong risk factor for prolonged methamphetamine psychosis. Pharmacogenomics. J. 3, 242-247.
  5. Sekine Y., Minabe Y., Ouchi Y., Takei N., Iyo M., Nakamura K., Suzuki K., Tsukada H., Okada H., Yoshikawa E., Futatsubashi M., Mori N. (2003) Association of dopamine transporter loss in the orbitofrontal and dorsolateral prefrontal cortices with methamphetamine-related psychiatric symptoms. Am. J. Psychiatry. 160, 1699-1701.
  6. Nakamura K., Iwahashi K., Furukawa A., Ameno K., Kinoshita H., Ijiri I., Sekine Y., Suzuki K., Iwata Y., Minabe Y., Mori N. (2003) Acetaldehyde adducts in the brain of alcoholics. Arch. Toxicol. 77, 591-593.
  7. Hashimoto K., Shimizu E., Komatsu N., Nakazato M., Okamura N., Watanabe H., Kumakiri C., Shinoda N., Okada S., Takei N., Iyo M. (2003) Increased levels of serum basic fibroblast growth factor in schizophrenia. Psychiatry Res. 120, 211-218.
  8. Nakazato M., Hashimoto K., Shimizu E., Kumakiri C., Koizumi H., Okamura N., Mitsumori M., Komatsu N., Iyo M. (2003) Decreased levels of serum brain-derived neurotrophic factor in female patients with eating disorders. Biol Psychiatry. 54, 485-490.
  9. Okamura N., Hashimoto K., Kanahara N., Shimizu E., Kumakiri C., Komatsu N., Iyo M. (2003) Protective effect of the antipsychotic drug zotepine on dizocilpine-induced neuropathological changes in rat retrosplenial cortex. Eur J Pharmacol. 461, 93-98.
  10. Okamura N., Hashimoto K., Shimizu E., Koike K., Ohgake S., Koizumi H., Kumakiri C., Komatsu N., Iyo M. (2003) Protective effect of LY379268, a selective group II metabotropic glutamate receptor agonist, on dizocilpine-induced neuropathological changes in rat retrosplenial cortex. Brain Res. 992, 114-119.
  11. Shimizu E., Hashimoto K., Okamura N., Koike K., Komatsu N., Kumakiri C., Nakazato M., Watanabe H., Shinoda N., Okada S., Iyo M. (2003) Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry. 54, 70-75.
  12. Shimizu E., Hashimoto K., Salama R.H., Watanabe H., Komatsu N., Okamura N., Koike K., Shinoda N., Nakazato M., Kumakiri C., Okada S., Muramatsu H., Muramatsu T., Iyo M. (2003) Two clusters of serum midkine levels in drug-naive patients with schizophrenia. Neurosci Lett. 344, 95-98.
  13. Shimizu E., Hashimoto K., Watanabe H., Komatsu N., Okamura N., Koike K., Shinoda N., Nakazato M., Kumakiri C., Okada S., Iyo M. (2003) Serum brain-derived neurotrophic factor (BDNF) levels in schizophrenia are indistinguishable from controls. Neurosci Lett. 351, 111-114.

原著 2002年

  1. Sekine Y., Minabe Y., Kawai M., Suzuki K., Iyo M., Isoda H., Sakahara H., Ashby C.R. Jr., Takei N., Mori N. (2002) Metabolite alterations in basal ganglia associated with methamphetamine-related psychiatric symptoms. A proton MRS study. Neuropsychopharmacology. 27, 453-461.
  2. Sakanoue M., Mori N., Takei N., Kawai M., Tani K., Suzuki K., Iwata Y., Sekine Y., Ashby C.R. Jr., Minabe Y. Tacrolimus, a specific inhibitor of calcineurin, modifies the locomotor activity of quinpirole, but not that of SKF82958, in male rats. (2002) Eur. J. Pharmacol. 438, 93-97.

原著 2001年

  1. Sekine Y., Iyo M., Ouchi Y., Matsunaga T., Tsukada H., Okada H., Yoshikawa E., Futatsubashi M., Takei N., Mori N. (2001) Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. Am. J. Psychiatry. 158, 1206-1214.
  2. Tsukamoto T., Iyo M., Tani K., Sekine Y., Hashimoto K., Ohashi Y., Suzuki K., Iwata Y., Mori N. (2001) The effects of FK506, a specific calcineurin inhibitor, on methamphetamine-induced behavioral change and its sensitization in rats. Psychopharmacology. 158, 107-113.
  3. Suzuki K., Omura S., Ohashi Y., Kawai M., Iwata Y., Tani K., Sekine Y., Takei N., Mori N. (2001) FK506 facilitates chemical kindling induced by pentylenetetrazole in rats. Epilepsy. Res. 46, 279-282.
  4. Tani K., Iyo M., Matsumoto H., Kawai M., Suzuki K., Iwata Y., Won T., Tsukamoto T., Sekine Y., Sakanoue M., Hashimoto K., Ohashi Y., Takei N., Mori N. (2001) The effects of dentate granule cell destruction on behavioural activity and Fos protein expression induced by systemic methamphetamine in rats. Br. J. Pharmacol. 134, 1411-1418.
  5. Matsunaga T., Tsukada H., Nishiyama S., Sekine Y., Kakiuchi T., Iyo M., Mori N. (2001) Yohimbine increases the binding potential for [11C] flumazenil in the monkey brain. J. Neural. Transm. 108, 1375-1382.

原著 1999年

  1. Ouchi Y., Yoshikawa E., Okada H., Futatsubashi M., Sekine Y., Iyo M., Sakamoto M. (1999) Alterations in binding site density of dopamine transporter in the striatum, orbitofrontal cortex, and amygdala in early Parkinson's disease. Compartment analysis for b-CFT binding with positron emission tomography. Ann. Neurol. 45, 601-610.

原著(日本語)

  1. 内田亜由美,田邊恭子,椎名明大,伊豫雅臣.(2016)青年期広汎性発達障害患者に対する集団認知行動療法の就労支援効果に関する試み.臨床精神医学.45(3), 357-365.
  2. 金原信久, 木村大, 渡邉博幸ら.(2015)治療抵抗性統合失調症に対する非定型抗精神病薬持効性注射剤の有用性.臨床精神薬理.18(6)747-755.
  3. 金原信久, 宗岡克政, 木村大ら.(2014)非定型持効性注射剤による統合失調症難治例への取り組み.精神科治療学.29(1)37-44.
  4. 金原信久, 鈴木智崇, 伊豫雅臣.(2014)Clozapineのより具体的な適応症例:治療抵抗性統合失調症の評価に際して.臨床精神薬理.17(2)261-275.
  5. 髙瀬正幸, 金原信久, 伊豫雅臣.(2014)定型抗精神病薬持効性注射剤の可能性:アドヒアランス維持とドパミン過感受性精神病の予防・改善.臨床精神薬理.17 (1)635-641.
  6. 金原信久, 木村大, 山中浩嗣ら.(2014)ドパミンD2受容体過感受性からみた治療抵抗性統合失調症の理解と治療戦略.臨床精神薬理. 17 (12)1617ー1623.
  7. 椎名明大,五十嵐禎人,伊豫雅臣.(2014)精神障害者の司法精神医学の認識に関する研究.司法精神医学.9(1),2-13.
  8. 伊豫雅臣, 椎名明大, 松原三郎, 川田和人, 吉川明弘, 三邉義雄, 畠稔, 福島秀行, 岩崎弥生, 小宮浩美, 小宮山徳太郎, 南風原泰, 篠田守, 佐々木一, 羽間京子, 佐竹直子.(2009)退院促進に関する精神医療の質的実態把握と最適化.精神神経学雑誌.111,9,1165-170.
  9. 椎名明大,松澤大輔,野間利昌,今井逸雄,渡辺博幸,野田慎吾,古関啓二郎,小河直之,大塚芳克,伊豫雅臣.(2004)統合失調症治療における従来型抗精神病薬からrisperidone単剤への切り替えに関する研究 -ハイブリッド型スイッチンクプロトコルによるパイロットスタディ-.臨床精神薬理.7,4,503-10.

症例・治験・手技

  1. A case of methamphetamine use disorder treated with the antibiotic drug minocycline. Tanibuchi Y., Shimagami M., Fukami G., Sekine Y., Iyo M., Hashimoto K. Gen Hosp Psychiatry. 2010 Sep-Oct;32(5):559.e1-3.
  2. Tanibuchi Y., Shimagami M., Fukami G., Sekine Y., Iyo M., Hashimoto K. A case of methamphetamine use disorder treated with the antibiotic drug minocycline. (in press) Gen. Hospital. Psychiatry.
  3. Nishimura K., Takei N., Suzuki K., Kawai M., Sekine Y., Isoda H., Mori N. (2006) A transient lesion in splenium of the corpus callosum in a patient with childhood-onset anorexia nervosa. Int. J. Eat. Disord. 39, 527-529.
  4. 中村愛, 星野良一, 安藤勝久, 小粥正博, 関根吉統, 河合正好, 森則夫. (2005) Methylphenidate 使用中に奇妙な絵画表現を呈した遷延性うつ病の1 例. 精神医学. 47, 491-497.
  5. 内田勝久, 武井教使, 鈴木勝昭, 関根吉統, 森則夫. (2005) 好中球減少によりclozapine 治験は中断したものの治験からもたらされた症状の改善は維持された症例. 臨床精神薬理. 8, 1997-2000.
  6. Sekine Y., Takei N., Suzuki K., Nakamura K., Tsuchiya K.J., Takebayashi K., Toulopoulou T., Mori N. (2005) Effective adjunctive use of pergolide with quetiapine for cognitive impairment and negative symptoms in schizophrenia. J. Clin. Psychopharmacol. 25, 281-283.
  7. Won M., Minabe Y., Sekine Y., Takei N., Kondo N., Mori N. (2003) Manic-switch induced by fluvoxamine in abstinent pure methamphetamine abusers. J. Psychiatry. Neurosci. 28, 134-135.
  8. Sekine Y., Takei N., Iyo M., Mori N., Minami M., Ohta T. (2001) Effective risperidone treatment for simple deteriorative disorder (simple schizophrenia). A case report. Schizophr. Res. 50, 213-214.
  9. Sekine Y., Iyo M., Tanaka K., Matsuyama K., Matsunaga T., Mori N. (2000) Effective adjunctive use of low-dose methylphenidate with mianserin for major depression with silent cerebral infarction. A case report. J. Clin. Psychopharmacol. 20, 584-585.
  10. Iyo M., Sekine Y., Matsunaga T., Tsukamoto T., Takei N., Mori N. Methamphetamine-associated obsessional symptoms and effective risperidone treatment: a case report. (1999) J. Clin. Psychiatry. 60:337-338.
  11. 谷邦彦, 伊豫雅臣, 塚本利雄, 関根吉統, 村主博史, 溝口勝美, 森則夫. (1999) 幻覚妄想状態や問題行動に対してrisperidone が有効であった老年期の2 症例. 臨床精神薬理. 2, 55-60.
  12. 松永勉, 三間清明, 太田憲輔, 谷邦彦, 塚本利雄, 関根吉統, 伊豫雅臣, 森則夫. (1998) 多発性脳梗塞を伴う diffuse neurofibrillary tangles with calcification と思われる1 臨床例. 精神医学. 40, 205-207.
  13. 小林一弘, 田中純二, 関根吉統, 大原浩市, 森則夫. (1997) Bifemelane ( セレポートR) と少量のSulpiride ( ドクマチールR) の併用が奏効した老年期うつ病の1 例. Prog. Med. 17, 1411-1413.

総説

  1. Oda Y, Kanahara N, Iyo M.(2015 Dec)Alterations of Dopamine D2 Receptors and Related Receptor-Interacting Proteins in Schizophrenia: The Pivotal Position of Dopamine Supersensitivity Psychosis in Treatment-Resistant Schizophrenia.Int J Mol Sci.17;16(12):30144-63.
  2. Shiina, A.(2015)Risk Assessment and Management of Violence in Patients with Mental Disorders: A Review.HSOA Journal of Forensic, Legal & Investigative Sciences.1,2.
  3. Shiina, A.(2015)Neurobiological Basis of Reactive Aggression: A Review. International Journal of Forensic Science & Pathology.3(3), 94-8.
  4. Shiina, A.(2013)Research Questions Regarding Mental Disorders and Violence.International Journal of Forensic Science & Pathology.1,1,1-2.
  5. Shiina, A.(2013)Current Issues around Child and Adolescent Behaviors.Journal of Child and Adolescent Behavior.1,e101.
  6. Shiina, A., Fujisaki, M., Iyo, M.(2013)Beyond Binder: Determination of Criminal Responsibility while in a State of Drunkenness by Japanese Courts.Journal of Forensic Research.s11.
  7. Ujike H., Inada T., Harano M., Komiyama T., Yamada M., Sekine Y., Iwata N., Iyo M., Sora I., Ozaki N. (2005) Candidate gene analysis of methamphetamine-related disorders. Neuropsychopharmacology 30, S24-S25.
  8. 渡邉 博幸.(2016 Feb)行動症状が目立つうつ病には、知的発達症が隠れているかもしれない.精神科臨床サービス.(1883-0463)16巻1号 Page46-49.
  9. 渡邉 博幸.(2016 Feb)治療抵抗性うつ病とされた甲状腺機能亢進症の女性例.精神科臨床サービス.(1883-0463)16巻1号 Page50-52.
  10. 髙瀬正幸,金原信久,伊像雅臣. (2017) 抗精神病薬:概論. 日本臨牀.印刷中.
  11. 渡邉博幸 (2016) 抗うつ薬を始める際に当事者に伝えること. 臨床精神薬理.20(3): 299−306.
  12. 髙瀬正幸,金原信久,伊像雅臣. (2016) 第2世代抗精神病薬持効性注射剤の用量設定および病状変化への急性対応:ドパミン感受性を考慮した検討の重要性. 臨床精神薬理.19(5): 585-595.
  13. 渡邉博幸 (2016) 抗精神病薬の適正使用に関する留意点. 精神科治療学.31(増)『統合失調症のベストプラクティス』: 139−142.
  14. 金原信久,伊像雅臣. (2016) ドパミン過感受性精神病:概念と治療アプローチ. 精神科治療学 31(増): 127-132.
  15. 渡邉 博幸.(2016)精神症状のある患者の身体疾患(身体合併症)治療.medicina.第53巻12号,2007−2010.
  16. 渡邉 博幸.(2016)気分安定化薬.薬局.67巻12号,137−141.
  17. 渡邉 博幸.(2016)双極性を有するうつ病の急性治療の現状と課題.臨床精神薬理.19巻11号,1573−1580.
  18. 渡邉 博幸.(2016)治療抵抗性うつ病とされた甲状腺機能亢進症の女性例.精神科臨床サービス.16巻1号,50-52
  19. 内田亜由美,田邊恭子,椎名明大,伊豫雅臣.(2016)青年期広汎性発達障害患者に対する集団認知行動療法の就労支援効果に関する試み.臨床精神医学.45(3), 357-365.
  20. 古関 麻衣子(千葉大学医学部附属病院 精神神経科), 橋本 佐, 金原 信久, 櫻井 大路, 築地 茉莉子, 長谷川 直, 伊豫 雅臣.(2015 Feb)双極性障害における治療薬調査および世界的ガイドラインと実臨床の比較研究(原著論文).Bipolar Disorder.13巻 Page29-35(2015.06)
  21. 渡邉博幸.(2015)統合失調症薬物療法の適正化はどのように行うのか? 不適正とならないための留意点.臨床精神薬理.18巻11号,1389-1397.
  22. 渡邉博幸.(2015)多職種チームで取り組むせん妄ケア・予防.Medical Alliance.1巻2号,142-148.
  23. 吉村健佑, 金原信久, 伊豫雅臣.(2015)ジストニア.精神科治療学.30増刊号: 393-395.
  24. 金原信久、渡邉博幸、伊豫雅臣.(2015)治療抵抗性統合失調症.精神科治療学.30増刊号: 40-43.
  25. 金原信久,木村大,渡邉博幸, 伊豫雅臣.(2015)治療抵抗性統合失調症に対する非定型抗精神病薬持効性注射剤の有用性.臨床精神薬理.2015, 18 (6).
  26. 渡邉博幸.(2014)統合失調症当事者の家族が治療を拒む時どうすれば良いか?.精神科治療学.29巻10号,1255-1260.
  27. 渡邉博幸.(2014)外来患者の暴言をどのように捉え対処するか?.精神科治療学.29巻10号,1229-1234.
  28. 渡邉博幸.(2014)統合失調症薬物療法の適正化に関する3つの提言.臨床精神薬理.17巻10号,1343-1352.
  29. 渡邉博幸.(2014)退院支援のための多職種チーム構築と実践 精神科医の立場から.精神科治療学.(0912-1862)29巻1号,19-24.
  30. 渡邉博幸.(2014)急性精神病状態に対するシンプル処方.臨床精神医学.43巻1号,11-17.
  31. 山本徹也、渡邉博幸、伊豫雅臣.(2014)強迫性障害および自閉症スペクトラム障害の併存が想定された治療抵抗性統合失調症のコンビネーションセラピー;Clozapine治療にSSRIおよび認知行動療法を組み合わせる.精神科治療学.29(9)1105-1112.
  32. 渡邉博幸.(2013)妊娠期・産褥期の電気痙攣療法.精神科治療学.(0912-1862)28巻5号,603-607.
  33. 渡邉博幸.(2013)統合失調症における抑うつ症状の薬物治療.精神科治療学.28巻1号,19−22.
  34. 渡邉博幸,吉野智,高野則之,色川大輔,長谷川信也,青木勉.(2012)千葉県東部における精神保健の取り組み-精神科多職種アウトリーチと中核地域生活支援センターとの連携-.精神科臨床サービス.12,216−220.
  35. 渡邉博幸.(2012)「抱える」医療から「つなぐ」医療へー総合病院精神科のダウンサイジングと地域精神医療の取り組みー.日本社会精神医学会雑誌.21,116-123.
  36. 渡邉博幸.(2012)多職種チームで取り組む地域精神医療の再構築―組織行動学的視点から組織変革をこころみる-.文化看護学会誌.4,66-76.
  37. 椎名明大,小田靖典,鈴木正利,吉澤雅弘,原口正,藤﨑美久,五十嵐禎人,伊豫雅臣.(2009)心神喪失者等医療観察法と地域サポート 医療観察法の現状と課題.社会精神医学会雑誌.18:2,252-8.
  38. 椎名明大.(2009)医療観察法で精神科医療は「底上げ」されるか.臨床精神薬理.38(5):739-45.
  39. 関根吉統. (2009) 覚せい剤精神疾患の画像による病態解析. 最新精神医学. 12, 139-146.
  40. 関根吉統, 橋本謙二, 伊豫雅臣. (2009) 依存の脳画像解析. Medical. Bio. 7, 36-41.
  41. 椎名明大.(2007)認知機能バッテリーについて.臨床精神薬理.10,7,1169-76.
  42. 鈴木千歌子, 関根吉統, 森則夫. (2007) 陰性症状及び認知機能障害に対するpergolide と抗精神病薬の併用療法. 最新精神医学. 12, 393-394.
  43. 関根吉統. (2006) 非定型抗精神病薬ペロスピロンの特性を探る.Medical. Tribune., Sep 28th, 107-108.
  44. 原野睦生, 内村直尚, 上野雄文, 安陪等思, 石橋正彦, 飯田信夫, 田中得雄, 前田久雄, 曽良一郎, 伊豫雅臣, 橋本謙二, 小宮山徳太郎, 山田光彦, 関根吉統, 稲田俊也, 尾崎紀夫, 岩田仲生, 氏家寛, 薬物依存ゲノム解析研究グループ(JGIDA). (2005) 覚せい剤関連精神障害の分子生物学的研究の進歩-覚せい剤精神病におけるドパミンレセプターD2 遺伝子Taq I A 多型と脳MRI. 日本アルコール精神医学雑誌. 12, 33-41.
  45. 伊豫雅臣, 関根吉統, 森則夫. (2004) 依存症のニューロサイエンス-主要な薬物依存症のニューロサイエンス的側面-覚醒剤関連精神障害のPET 画像. Clinical. Neuroscience. 22, 696-698.
  46. 氏家寛, 稲田俊也, 原野睦生, 小宮山徳太郎, 山田光彦, 関根吉統, 曽良一郎, 岩田仲生, 伊豫雅臣, 尾崎紀夫. (2004) 遺伝子研究によってどこまで精神疾患の病態は解明されたか-薬物依存と遺伝子関連研究. 精神神経学雑誌. 106, 1598-1603.
  47. 氏家寛, 勝強志, 関根吉統, 稲田俊也. (2003) 依存性薬物の精神薬理-メタンフェタミン精神病の分子遺伝学-. 臨床精神薬理. 6, 1135-1141.
  48. 関根吉統, 伊豫雅臣, 森則夫. (2002) 中毒性・依存性薬物の分子作用機序-覚せい剤依存者における脳内神経伝達系の変化-. 分子精神医学. 2, 55-61.
  49. 関根吉統, 伊豫雅臣. (2001) 覚せい剤精神病の発現機序に関する臨床研究-ポジトロンCT 及びプロトンMRS を用いて-. 日本神経精神薬理学雑誌. 21, 177-178.
  50. 伊豫雅臣, 関根吉統, 河合正好, 森則夫. (2000) 薬物依存研究の最新知見-覚醒剤精神病のイメージング-. 脳の科学. 22, 433-438.
  51. 関根吉統, 伊豫雅臣, 森則夫. (2000) 薬物乱用者における脳障害の画像解析. 精神医学. 42(4), 338-344.

著書

  1. 渡邉博幸 (2017) 抗精神病薬. 高久史麿監. 堀正二他編:治療薬ハンドブック2017. じほう. 東京: 101−110.
  2. 渡邉博幸 (2016) 統合失調症スペクトラム障害(統合失調症)への日常診療−10分間を有効に活かすための工夫−. 中村敬編:日常診療における精神療法10分間で何ができるか. 星和書店. 東京: 27−39.
  3. 椎名明大 (2016) 物質関連障害及び嗜癖性障害群への対処. 中村敬編:日常診療における精神療法 10分間で何ができるか. 星和書店. 東京: 177-192.
  4. 岩崎弥生・渡邉博幸編著.(2016.01)新体系 看護学全書 精神看護学②精神障害をもつ人の看護.メヂカルフレンド社.2.
  5. 渡邉博幸.(2016)錐体外路系副作用に推奨される治療法および予防法は?.日本神経精神薬理学会編:統合失調症薬物治療ガイドライン,医学書院,東京,121−135,2016.
  6. 渡邉博幸.(2016)統合失調症の抑うつ状態に対してどのような薬物治療が有効か?.日本神経精神薬理学会編:統合失調症薬物治療ガイドライン.医学書院,東京.p108−111.
  7. 渡邉博幸.(2016)地域で支える産後うつ病−多職種ミーティングの活用−.岡野禎治他編:クロストークから読み解く周産期メンタルヘルス.南山堂,東京.p9−12,p143−150.
  8. 岩崎弥生, 渡邉博幸編著.(2015.12)新体系 看護学全書 精神看護学①精神看護学概論・精神保健. メヂカルフレンド社.1.
  9. 渡邉博幸.(2014)病気と治療の説明 1.本人への説明と病名告知−病を名付け,説明することの力について−. 大森哲郎監修:統合失調症ケーススタディー〜症例が導く社会復帰・QOL向上への道〜.メディカルレビュー社,大阪, p49-50.
  10. 酒井郁子,渡邉博幸編.(2014)どうすればよいか?に答えるせん妄のスタンダードケアQ&A100. 南江堂,東京.
  11. 渡邉博幸 石郷岡純,後藤雅博,水野雅文,福田雅人編.(2012)地域における効果のみられたチーム医療.統合失調症第3巻 効果のみられたチーム医療.医薬ジャーナル社,大阪.統合失調症第3巻 90−100.
  12. 中谷陽二,五十嵐禎人,椎名明大.(2010)だれでもわかる精神医学用語集―裁判員制度のために.民事法研究会,東京.
  13. 渡辺真俊,椎名明大.(2005)心神喪失者等医療観察法による医療,司法精神医学5司法精神医療.山内俊夫編,中山書店,東京.132-139.
  14. 関根吉統. (in press) 覚せい剤精神病/ドパミン・トランスポーター. キーワード279で読み解く精神医学, 中山書店.
  15. 伊豫雅臣, 橋本謙二, 関根吉統. (2009) 覚せい剤関連精神疾患. 病気と薬パーフェクトBOOK 2009, 南山堂. 897-900.
  16. 伊豫雅臣, 関根吉統, 森則夫. (2004) 覚せい剤精神病と麻薬依存-覚せい剤精神病の脳機能画像所見. 覚せい剤精神病と麻薬依存. 東北大学出版会. 20-29.
  17. 伊豫雅臣, 関根吉統. (2003) 覚せい剤関連精神障害. 領域別症候群シリーズ, 日本臨牀社. 507-512.伊豫雅臣, 関根吉統. (2003) 覚せい剤関連精神障害. 領域別症候群シリーズ, 日本臨牀社. 507-512.
  18. 近藤直樹, 関根吉統. (1999) 覚せい剤依存と関連精神障害-薬理作用乱用状況. 臨床精神医学講座. 8, 中山書店. 209-221.

訳書

  1. Robert Ladouceur, Stella Lachance (著) 椎名明大・長谷川直・伊豫雅臣(翻訳).(2015)ギャンブル障害の治療:治療者向けガイド ‐認知行動療法によるアプローチ‐.星和書店,東京.
  2. Robert Ladouceur, Stella Lachance (著) 椎名明大・長谷川直・伊豫雅臣(翻訳).(2015)ギャンブル障害の治療: 患者さん向けワークブック ‐認知行動療法によるアプローチ‐.星和書店,東京.

ページトップへ